Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 69.0%

Gross margin was 69.0% in Q1 FY2026, up 7.8 pp from a year earlier. On a trailing-twelve-month basis it was 52.6%, up 22.8 pp year over year.

Context

  • Gross margin widened in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
69.0%-2.3 pp QoQ
Last fiscal yearDec 2025
34.7%+11.6 pp YoY
LTMMar 2026
52.6%+22.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.8 pp——
1 year+11.6 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
34.7%
Year-over-year change
+11.6pp

Gross Margin vs competitors

How TNXP compares with its peers on the latest reported figures

  • TNXP's LTM Mar 2026 gross margin of 52.6% is the 3rd highest of the 6 companies compared; the peer median is -20.9%.
  • Its year-over-year change of +22.8 pp is the 2nd highest of 4, against a peer median of +0.0 pp.
TNXP Competitors Peer median
Gross Margin for TNXP and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
MISTMilestone Pharmaceuticals Inc.LTM Mar 202694.7% —-7.4 pp
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 202652.6% +22.8 pp—
MCRBSeres Therapeutics, Inc.LTM Mar 2026-20.9% ——
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-17996.6% -16820.4 pp+19.0 pp
FBRXForte Biosciences, Inc.FY2025— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
NKTXNkarta, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding TNXP) -20.9%+0.0 pp+5.8 pp

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.